{"id":"https://openalex.org/W4404025540","doi":"https://doi.org/10.1158/1078-0432.27609926","title":"Supplementary Methods from Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody\u2013Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non\u2013Small Cell Lung Carcinoma","display_name":"Supplementary Methods from Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody\u2013Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non\u2013Small Cell Lung Carcinoma","publication_year":2024,"publication_date":"2024-11-04","ids":{"openalex":"https://openalex.org/W4404025540","doi":"https://doi.org/10.1158/1078-0432.27609926"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.27609926","doi":"https://doi.org/10.1158/1078-0432.27609926","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.27609926","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Methods_from_Phase_I_Study_of_2-_or_3-Week_Dosing_of_Telisotuzumab_Vedotin_an_Antibody_Drug_Conjugate_Targeting_c-Met_Monotherapy_in_Patients_with_Advanced_Non_Small_Cell_Lung_Carcinoma/27609926/1/files/50202797.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Methods_from_Phase_I_Study_of_2-_or_3-Week_Dosing_of_Telisotuzumab_Vedotin_an_Antibody_Drug_Conjugate_Targeting_c-Met_Monotherapy_in_Patients_with_Advanced_Non_Small_Cell_Lung_Carcinoma/27609926/1/files/50202797.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082517668","display_name":"D. Ross Camidge","orcid":"https://orcid.org/0000-0003-3430-3213","observed_orcids":["https://orcid.org/0000-0003-3430-3213"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Ross Camidge","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031420337","display_name":"Daniel Morgensztern","orcid":"https://orcid.org/0000-0003-4349-2028","observed_orcids":["https://orcid.org/0000-0003-4349-2028"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Morgensztern","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064382279","display_name":"Rebecca Suk Heist","orcid":"https://orcid.org/0000-0002-7397-2009","observed_orcids":["https://orcid.org/0000-0002-7397-2009"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rebecca S. Heist","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015591858","display_name":"Minal A. Barve","orcid":"https://orcid.org/0009-0007-4259-7457","observed_orcids":["https://orcid.org/0009-0007-4259-7457"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Minal Barve","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Everett Vokes","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8645-8068","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036134937","display_name":"Jonathan Wade Goldman","orcid":"https://orcid.org/0000-0002-4925-8243","observed_orcids":["https://orcid.org/0000-0002-4925-8243"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan W. Goldman","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4925-8243","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David S. Hong","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8721-1609","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037195922","display_name":"Todd Michael Bauer","orcid":"https://orcid.org/0000-0002-3078-5043","observed_orcids":["https://orcid.org/0000-0002-3078-5043"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Todd M. Bauer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005968330","display_name":"John H. Strickler","orcid":"https://orcid.org/0000-0001-7579-1175","observed_orcids":["https://orcid.org/0000-0001-7579-1175"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John H. Strickler","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7579-1175","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028436035","display_name":"Eric Angevin","orcid":"https://orcid.org/0000-0001-6249-7209","observed_orcids":["https://orcid.org/0000-0001-6249-7209"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric Angevin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103552874","display_name":"Monica Motwani","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Monica Motwani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011356640","display_name":"Apurvasena Parikh","orcid":"https://orcid.org/0000-0003-3711-8718","observed_orcids":["https://orcid.org/0000-0003-3711-8718"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Apurvasena Parikh","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3711-8718","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079615978","display_name":"Zhaowen Sun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhaowen Sun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042122044","display_name":"Bruce Allen Bach","orcid":"https://orcid.org/0000-0003-3535-9518","observed_orcids":["https://orcid.org/0000-0003-3535-9518"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce Allen Bach","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101407043","display_name":"Jun Wu","orcid":"https://orcid.org/0000-0002-6922-8762","observed_orcids":["https://orcid.org/0000-0002-6922-8762"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jun Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033776778","display_name":"Philip B. Komarnitsky","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philip B. Komarnitsky","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5077352149","display_name":"Karen L. Kelly","orcid":"https://orcid.org/0000-0002-2235-6636","observed_orcids":["https://orcid.org/0000-0002-2235-6636"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karen Kelly","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2235-6636","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12992","display_name":"Metastasis and carcinoma case studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/telisotuzumab-vedotin","display_name":"telisotuzumab vedotin","score":1.0},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9750000238418579},{"id":"https://openalex.org/keywords/c-met","display_name":"c-Met","score":0.9879999756813049},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8799999952316284},{"id":"https://openalex.org/keywords/advanced-lung-cancer","display_name":"advanced lung cancer","score":0.699999988079071},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.7310000061988831},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.6190000176429749},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.9850000143051147},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.7730000019073486}],"concepts":[{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.8026146292686462},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.7583872675895691},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7165657877922058},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.691917896270752},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5755756497383118},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5530845522880554},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4849007725715637},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4743988513946533},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4484255611896515},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4067858159542084},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.3115156292915344},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.17312976717948914},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.16647693514823914},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C134306372","wikidata":"https://www.wikidata.org/wiki/Q7754","display_name":"Mathematical analysis","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.27609926","doi":"https://doi.org/10.1158/1078-0432.27609926","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.27609926","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Methods_from_Phase_I_Study_of_2-_or_3-Week_Dosing_of_Telisotuzumab_Vedotin_an_Antibody_Drug_Conjugate_Targeting_c-Met_Monotherapy_in_Patients_with_Advanced_Non_Small_Cell_Lung_Carcinoma/27609926/1/files/50202797.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/27609926","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Methods_from_Phase_I_Study_of_2-_or_3-Week_Dosing_of_Telisotuzumab_Vedotin_an_Antibody_Drug_Conjugate_Targeting_c-Met_Monotherapy_in_Patients_with_Advanced_Non_Small_Cell_Lung_Carcinoma/27609926","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.27609926","doi":"https://doi.org/10.1158/1078-0432.27609926","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.27609926","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Methods_from_Phase_I_Study_of_2-_or_3-Week_Dosing_of_Telisotuzumab_Vedotin_an_Antibody_Drug_Conjugate_Targeting_c-Met_Monotherapy_in_Patients_with_Advanced_Non_Small_Cell_Lung_Carcinoma/27609926/1/files/50202797.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8999999761581421}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4404025540.pdf","grobid_xml":"https://content.openalex.org/works/W4404025540.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3194878909","https://openalex.org/W4404025507","https://openalex.org/W2981328918","https://openalex.org/W2894761459","https://openalex.org/W7220826907","https://openalex.org/W3205823644","https://openalex.org/W4200243391","https://openalex.org/W4248096473","https://openalex.org/W7220781098","https://openalex.org/W4388655064"],"abstract_inverted_index":{"Supplementary":[0],"Methods":[1],"includes":[2],"study":[3],"design,":[4],"antitumor":[5],"activity,":[6],"and":[7],"exploratory":[8],"biomarkers":[9]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2024-11-04T00:00:00"}